castrationresistant

Treatment of Nonmetastatic Castration-Resistant Prostate Cancer.
Patients with nonmetastatic castration-resistant prostate cancer (CRPC) are a heterogeneous population with regard to risk of progression to metastatic disease. Treatment selection for nonmetastatic CRPC must balance the risk of disease progression ... [...]
2
Like
Save
Prognosis of Castration-resistant Prostate Cancer Patients – Use of the …
Detection of circulating tumor cells (CTC) in patients with castration-resistant prostate cancer (CRPC) may improve the estimate of chemotherapy response. We evaluated ... The sPSA level correlated with CTC positivity during docetaxel therapy (p=0.0031). [...]
1
Like
Save
SRC-2 drives castration-resistant prostate cancer
Finding a blocker for the nuclear receptor coactivator known as NCoA2 or SRC-2 might solve the problem of treating advanced prostate cancer that becomes resistant to the most common treatment – drugs that deprive the body of androgens, or male ... [...]
1
Like
Save
Abiraterone acetate in metastatic castration-resistant prostate cancer – the …
We report the clinical outcome of metastatic castration-resistant prostate cancer (mCRPC) patients treated with AA in real-life clinical practice. The clinical records of mCRPC patients treated with AA from all 6 public oncology centers in Hong Kong ... [...]
4
Like
Save
Enzalutamide Superior to Bicalutamide in Castration-resistant Prostate Cancer
Survival with enzalutamide, an androgen inhibitor, was superior to bicalutamide in the treatment of men with castration-resistant prostate cancer (CRPC).1 Bicalutamide is currently the most common antiandrogen agent used in the second-line treatment of ... [...]
6
Like
Save
Sphingosine kinase inhibitor slows castration-resistant prostate cancer cell …
This study is the first to show activity for this compound against DEGS and to potentially link inhibition of DEGS to slowing the growth of castration-resistant prostate cancer cells. Treatment with YELIVA™ (ABC294640) increased dihydroceramide levels ... [...]
6
Like
Save
Secondary Hormone Therapy for Castration-Resistant Prostate Cancer
The majority of patients with systemic prostate cancer treated with androgen deprivation therapy (ADT) will develop castration-resistant prostate cancer (CRPC). CRPC is defined by prostate-specific antigen (PSA) or radiographic progression in the ... [...]
4
Like
Save
A new class of drug slows growth of castration-resistant prostate cancer cells
This study is the first to show activity for this compound against DEGS and to potentially link inhibition of DEGS to slowing the growth of castration-resistant prostate cancer cells. Treatment with YELIVA™ (ABC294640) increased dihydroceramide levels ... [...]
3
Like
Save